SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Organicell Regenerative Medicine, Inc. – ‘8-K’ for 8/6/20

On:  Thursday, 8/6/20, at 8:00am ET   ·   For:  8/6/20   ·   Accession #:  1683168-20-2530   ·   File #:  0-55008

Previous ‘8-K’:  ‘8-K’ on 7/14/20 for 6/24/20   ·   Next:  ‘8-K’ on / for 8/13/20   ·   Latest:  ‘8-K’ on / for 3/4/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/06/20  Organicell Regenerative Medi… Inc 8-K:8,9     8/06/20    2:29K                                    GlobalOne Filings Inc/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     13K 
 2: EX-99.1     Press Release                                       HTML     11K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 6, 2020

 

ORGANICELL REGENERATIVE MEDICINE, INC.

(Exact name of registrant as specified in its charter)

 

Nevada 000-55008 47-4180540
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation)   Identification No.)

 

4045 Sheridan Avenue, Suite 239, Miami, FL        33140

(Address of Principal Executive Offices)          (Zip Code)

 

Registrant's telephone number, including area code: (888) 963-7881

 

_________________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class Trading Symbol Name of each exchange on which registered
None  N/A  N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

 

 

 

 

 

 C: 
 C:    

 

 

As used in this Current Report on Form 8-K, and unless otherwise indicated, the terms “the Registrant”, the Company,” Organicell,” we,”us” and “our” refer to Organicell Regenerative Medicine, Inc.

 

Item 8.01 Other Events.

 

On August 6, 2020, Organicell issued a press release in which it announced that the U.S. Food and Drug Administration (FDA) approved two outpatient Emergency Investigational New Drug Applications (eINDs) for treating mild to moderate respiratory distress due to COVID-19.

 

A copy of the Company’s press release dated August 6, 2020 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No   Description
     
99.1   Press Release, August 6, 2020

 

  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Dated: August 6, 2020 ORGANICELL REGENERATIVE MEDICINE, INC.
   
   
  By:  /s/ Ian Bothwell
    Ian Bothwell
Chief Financial Officer

 

 

 

 

 

 C: 
 C: 2  


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:8/6/203,  4
 List all Filings 
Top
Filing Submission 0001683168-20-002530   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 6:34:12.1pm ET